Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B-Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04425824
What this trial is testing

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell LymphomaRituximabToripalimab
Chinese Academy of Medical Sciences 20
Early research (Phase 1)Looking for participantsNCT06859008
What this trial is testing

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT01118013
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Who this might be right for
LeukemiaLymphomaLymphoproliferative Disorder+3 more
Alliance for Clinical Trials in Oncology 6
Early research (Phase 1)Study completedNCT02795182
What this trial is testing

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Who this might be right for
LymphomaLeukemia
BeiGene 75
Early research (Phase 1)Study completedNCT01429025
What this trial is testing

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology 26
Testing effectiveness (Phase 2)Looking for participantsNCT07001540
What this trial is testing

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Who this might be right for
Diffuse Large B-Cell Lymphoma
Fudan University 130
Testing effectiveness (Phase 2)Looking for participantsNCT03676504
What this trial is testing

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Who this might be right for
Acute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, PediatricChronic Lymphocytic Leukemia+3 more
University Hospital Heidelberg 68
Large-scale testing (Phase 3)Study completedNCT01014208
What this trial is testing

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Lymphoma, Large-Cell, Diffuse
GlaxoSmithKline 447
Very early researchNot Yet RecruitingNCT07168291
What this trial is testing

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Burkitt Lymphoma
First Affiliated Hospital Xi'an Jiaotong University 3
Testing effectiveness (Phase 2)Study completedNCT00452374
What this trial is testing

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 48
Testing effectiveness (Phase 2)WithdrawnNCT04285268
What this trial is testing

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell Lymphoma+4 more
Rutgers, The State University of New Jersey
Post-approval studies (Phase 4)Looking for participantsNCT06134284
What this trial is testing

Clinical Study of OR for Second-line Treatment of Refractory MZL

Who this might be right for
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng 39
Testing effectiveness (Phase 2)Study completedNCT02399085
What this trial is testing

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
MorphoSys AG 81
Testing effectiveness (Phase 2)Study completedNCT01076543
What this trial is testing

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Who this might be right for
AIDS-Related Hodgkin LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Follicular Lymphoma+5 more
National Cancer Institute (NCI) 110
Early research (Phase 1)Study completedNCT00077558
What this trial is testing

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not applicableNot Yet RecruitingNCT07472621
What this trial is testing

Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Henan Cancer Hospital 20
Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Testing effectiveness (Phase 2)Study completedNCT00053989
What this trial is testing

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
Roswell Park Cancer Institute 41
Early research (Phase 1)Study completedNCT04450069
What this trial is testing

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Who this might be right for
Relapsed/Refractory B-cell LymphomasDiffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more
Calibr, a division of Scripps Research 18
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Next Page
37